MediMix Oncology
  • Home
  • Congresses
    • 2026
      • ASCO 2026
      • ELCC 2026
      • ENETS 2026
      • BSMO 50 YEARS
      • ASCO GU 2026
      • ASCO GI 2026
    • 2025
      • SABCS 2025
      • SIOG 2025
      • ESMO 2025
      • WCLC 2025
      • ESMO GI 2025
      • EADO 2025
  • STiP
  • Webinars
    • ESDO – GI Cancer – ASCO GI 2026
    • ESDO GI Cancer – ESMO 2025
  • Contact
  • Other specialties
    • Dermatology
    • Hematology
    • Respirology
    • Cardiology
    • Rheumatology
    • Neurology
  • SIGN UP
  • SIGN IN
    • Login
    • Account
ESMO 2023GI

Cell line study of nucleosome-based biomarkers in the diagnosis and detection of relapses in glioblastoma

28 October 2023

Jonathan Decarpentrie, PhD researcher at the university of Namur presented his project focusing on the detection of epigenetic modifications of nucleosomes in glioblastoma by means of the Nu. Q® technology tool.

 

 

You may also be interested in:

The AVETUXIRI phase II study

27 October 2023

R-IMMUNE study: atezolizumab in locally advanced rectal cancer

26 October 2023

Prognosis in stage II colorectal cancer: The effect of the primary tumor location and biomarkers

25 October 2023

With the educational support of:

Tags:

poster

Share Article

Website created by MediMix © 2026 - Privacy Policy

  • Home
  • Congresses
    • 2026
      • ASCO 2026
      • ELCC 2026
      • ENETS 2026
      • BSMO 50 YEARS
      • ASCO GU 2026
      • ASCO GI 2026
    • 2025
      • SABCS 2025
      • SIOG 2025
      • ESMO 2025
      • WCLC 2025
      • ESMO GI 2025
      • EADO 2025
  • STiP
  • Webinars
    • ESDO – GI Cancer – ASCO GI 2026
    • ESDO GI Cancer – ESMO 2025
  • Contact
  • Other specialties
    • Dermatology
    • Hematology
    • Respirology
    • Cardiology
    • Rheumatology
    • Neurology
  • SIGN UP
  • SIGN IN
    • Login
    • Account
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.